Darren Sherman

Darren Sherman is a Managing Partner of Orchestra. He is also Chief Technical Officer of Accelerated Technologies, Inc. (ATI) as well as Chief Executive Officer of Caliber Therapeutics, Inc., an OMV II Fund Portfolio Company. He has over 17 years of management and entrepreneurial experience in the medical technology industry spanning interventional cardiology, cardiac electrophysiology, sudden cardiac death, stroke, and neurovascular therapies. He currently serves as a director of Caliber Therapeutics and Vivasure Medical. Prior to joining Orchestra, Mr. Sherman held various positions in executive management for Cordis Neurovascular (CNV), a Johnson & Johnson company, including Executive Director R&D and Director of Strategic Marketing for stroke products. He had worldwide responsibility for all neurovascular R&D and global strategic marketing responsibilities for the Stroke franchise, including budgets, portfolio of products and strategic planning. Mr. Sherman made significant contributions to the design and commercialization of a series of key products including the Enterprise Vascular Reconstruction Device and the Orbit Embolic Coil as well as directed the filing of over 100 patents. Prior to joining CNV, Mr. Sherman played an integral role in the formation and development of Revivant Corp (acquired by Zoll) while working with Thomas J. Fogarty, MD at Fogarty Engineering. He was Revivant's first employee and managed the design, development, and testing of the AutoPulse device from concept through market introduction. In addition to the R&D related activities, Mr. Sherman supported the clinical research, marketing, and intellectual property efforts. The AutoPulse is a lightweight, portable tool replacing the need for manual chest compressions during cardio-pulmonary resuscitation (CPR) for patients suffering from sudden cardiac arrest. Prior to Revivant, Mr. Sherman held positions in research and development for Cardiac Pathways Corp., prior to its acquisition by Boston Scientific, and Baxter Healthcare. In each of these companies, he participated in the creation, development and launch of products. Mr. Sherman has authored 45 U.S. patents with an additional 58 published applications. He earned a BS degree in Bioengineering from the University of California, San Diego.